Product-Specific Guidances for Complex Generic Drugs

Non-Complex Drug Products and Product-Specific Guidances

FDA-USP-AAM | D1S3 - Industry’s Engagement in USP’s Standards-Setting Process

Complex Peptide ANDAs: Test/Reference Comparability (11of35) Complex Generics – Sep. 25-26, 2019

FDA Grand Rounds - Adopting Large Language Models for Regulatory Review

FDA Grand Rounds - Antibody Glycosylation Insights for High Quality Biotherapeutics

Conversations on Cancer – Perspectives on Cancer Care Decision-Making Among Older Adults

OTC Monograph Reform: OTC Sunscreen Drugs

FDA Grand Rounds - Advancing Real World Evidence in FDA Regulatory Decision Making

FDA Expert Panel on Food Allergies

Alternatives to f2 Testing for Dissolution Similarity – f2 Bootstrapping and MSD Method

Complex Generics: Nasal and Inhalation Products

Drug Master File (DMF) Submissions on New FDA Form 3938

FDA Grand Rounds - Postmarket Regulation of Cosmetic Products: The Who, What, When, Why, and How

FDA Direct: Combating Rare Diseases at the FDA

FDA Grand Rounds - Anti biofilm Technologies for Enhancing the Safety of Medical Device Surfaces

Advancing Generic Drug Development: Translating Science to Approval – Day 1 – Session 3

FDA-USP-AAM | D1S1 – FDA's Participation in USP-NF Revision Process – Challenges and Solutions

FDA's Public Meeting on Food Allergen Thresholds - 02/18/2026

Quality Considerations for Generic Orally Inhaled Drug Products (35of39) Complex Generics 2018

FDA Grand Rounds - Statistical Considerations for Drug Development in Rare Disease